Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.9
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100,...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers.
Data is available to registered users only
Target Price
Buy
Sell